|By PR Newswire||
|March 18, 2014 06:04 PM EDT||
NEW YORK, March 18, 2014 /PRNewswire/ -- (PR Newswire) – FRANK & BIANCO LLP is investigating potential securities fraud claims against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain of its officers, on behalf of purchasers of Geron's securities between June 16, 2013 and March 11, 2014, inclusive (the "Class Period").
The investigation concerns possible violations of the federal securities laws that occurred when the Company and certain of its officers issued materially false and misleading statements or omitted to state material information during the Class Period regarding imetelstat, Geron's first-in-class telomerase inhibitor currently in development for the treatment of hematologic malignancies. As a result of these misstatements and omissions, Geron's securities traded at artificially inflated prices throughout the Class Period.
On March 12, 2014, the Company issued a press release announcing that the U.S. Food and Drug Administration ("FDA") had halted clinical trials of imetelstat. The FDA cited concerns about persistent liver function test ("LFT") abnormalities reported in patients participating in clinical trials, and the potential risk of chronic liver injury following long-term exposure to the drug. In addition, the FDA expressed concern about whether the reported LFT abnormalities are reversible. On this news, the Company's stock price dropped $2.71 per share, more than 60%, on heavy trading volume.
If you purchased Geron securities within the Class Period, and you wish to discuss this investigation, or have any questions concerning this notice or your rights or interests with respect to these matters, please contact us.
SOURCE Frank & Bianco LLP
Jan. 20, 2017 06:30 PM EST Reads: 5,444
Jan. 20, 2017 05:45 PM EST Reads: 2,085
Jan. 20, 2017 05:30 PM EST Reads: 1,462
Jan. 20, 2017 05:15 PM EST Reads: 4,942
Jan. 20, 2017 05:15 PM EST Reads: 3,801
Jan. 20, 2017 05:15 PM EST Reads: 3,531
Jan. 20, 2017 04:45 PM EST Reads: 1,070
Jan. 20, 2017 03:00 PM EST Reads: 1,641
Jan. 20, 2017 02:30 PM EST Reads: 1,118
Jan. 20, 2017 02:15 PM EST Reads: 607
Jan. 20, 2017 01:30 PM EST Reads: 5,233
Jan. 20, 2017 01:30 PM EST Reads: 3,591
Jan. 20, 2017 01:30 PM EST Reads: 5,729
Jan. 20, 2017 01:00 PM EST Reads: 2,575
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Jan. 20, 2017 12:30 PM EST Reads: 4,345